Physician profile
Deborah Karm
NPI 1124431374
$5,661.06
in general payments reported to CMS, 2019-2025
52 companies · $534 in 2025
The $534 reported for 2025 was more than what 82% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $804 · 2020: $1,131 · 2021: $1,682 · 2022: $838 · 2023: $325 · 2024: $347 · 2025: $534.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,205.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $734.87 | 2019-2025 | |
| Glaxosmithkline, LLC. | $414.01 | 2019-2022 | |
| Therapeuticsmd, INC. | $408.92 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $288.40 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $279.50 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $247.00 | 2020-2022 | |
| Myovant Sciences INC. | $233.54 | 2021-2022 | |
| Sage Therapeutics, LLC | $231.62 | 2022-2025 | Zurzuvae |
| Janssen Biotech, INC. | $217.09 | 2020-2022 | |
| Pfizer INC. | $209.64 | 2020-2024 | |
| Mayne Pharma Commercial LLC | $160.21 | 2022-2025 | |
| Shield Therapeutics INC | $132.89 | 2023-2025 | Accrufer |
| Astellas Pharma US INC | $129.68 | 2023-2025 | Veozah |
| Lilly USA, LLC | $125.50 | 2019-2021 | |
| Exeltis, USA INC. | $116.92 | 2020-2023 | Slynd |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deborah Karm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.